- Home
- PTGX vs CSQ Comparison
PTGX vs CSQ Comparison
Compare PTGX & CSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- CSQ
- Stock Information
- Founded
- PTGX 2006
- CSQ 2003
- Country
- PTGX United States
- CSQ United States
- Employees
- PTGX N/A
- CSQ N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- CSQ Finance Companies
- Sector
- PTGX Health Care
- CSQ Finance
- Exchange
- PTGX Nasdaq
- CSQ Nasdaq
- Market Cap
- PTGX 3.3B
- CSQ 2.8B
- IPO Year
- PTGX 2016
- CSQ N/A
- Fundamental
- Price
- PTGX $53.00
- CSQ $18.26
- Analyst Decision
- PTGX Strong Buy
- CSQ
- Analyst Count
- PTGX 9
- CSQ 0
- Target Price
- PTGX $67.11
- CSQ N/A
- AVG Volume (30 Days)
- PTGX 949.2K
- CSQ 220.3K
- Earning Date
- PTGX 08-05-2025
- CSQ 01-01-0001
- Dividend Yield
- PTGX N/A
- CSQ 7.53%
- EPS Growth
- PTGX N/A
- CSQ N/A
- EPS
- PTGX 0.86
- CSQ N/A
- Revenue
- PTGX $207,801,000.00
- CSQ N/A
- Revenue This Year
- PTGX N/A
- CSQ N/A
- Revenue Next Year
- PTGX $53.09
- CSQ N/A
- P/E Ratio
- PTGX $61.45
- CSQ N/A
- Revenue Growth
- PTGX N/A
- CSQ N/A
- 52 Week Low
- PTGX $32.50
- CSQ $12.50
- 52 Week High
- PTGX $60.60
- CSQ $16.45
- Technical
- Relative Strength Index (RSI)
- PTGX 53.99
- CSQ 64.90
- Support Level
- PTGX $49.38
- CSQ $18.15
- Resistance Level
- PTGX $51.51
- CSQ $18.35
- Average True Range (ATR)
- PTGX 2.02
- CSQ 0.21
- MACD
- PTGX -0.39
- CSQ -0.01
- Stochastic Oscillator
- PTGX 46.09
- CSQ 82.46
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.